Chargement de la fiche…
Chargement de la fiche…
MonRhumato.fr utilise des cookies pour mesurer l'audience (statistiques) et améliorer le site. Aucune donnée de santé identifiable n'est jamais collectée. Politique de confidentialité.
Votre choix est conservé 13 mois (durée max CNIL). Vous pouvez le modifier à tout moment via Préférences cookies.
4 raisons identifiées
Plateau technique de référence
Assistance publique – Hôpitaux de Paris (APHP) — équipements et expertise pointus pour les cas complexes
Auteur de référence en rhumatologie
33 articles scientifiques publiés — un praticien à la pointe de la recherche
Expérience confirmée
21 ans d'exercice en rhumatologie — recul clinique solide
Délais de RDV courts dans la région
134 rhumatos / 100 000 hab. — département bien doté
21ans d'exercice (thèse 2005)
✨ Génération du profil synthétique IA en cours…
Données ANS publiques (Licence Ouverte 2.0) · Enrichissements MonRhumato 100 % opt-in · Toute personne référencée peut demander la suppression ou la rectification.
Source : catalogue national des thèses theses.fr (ABES). Ne couvre que les doctorats / HDR — les thèses d'exercice (DES) sont archivées dans les SCD universitaires.
Indicateurs publics agrégés sur 250 M+ d'œuvres scientifiques (OpenAlex, PubMed). Traduits ici en langage patient.
Influence scientifique
56
56 articles ont été cités au moins 56fois par d'autres chercheurs — preuve que ses travaux sont repris par la communauté médicale.
h-index
Total citations reçues
16 793
Nombre de fois où d'autres équipes ont mentionné ses publications dans leurs propres travaux.
Publications totales
416
Articles, revues et chapitres référencés dans les bases académiques internationales.
Articles influents
164
Publications ayant marqué leur domaine — chacune citée au moins 10 fois par d'autres chercheurs.
i10-index
Thématiques principales
Affiliations FR : Inserm · Université Paris-Est Créteil · Centre Hospitalier Universitaire Henri-Mondor
Source : OpenAlex (CC0, OurResearch). Indicateurs académiques agrégés sur 250 M+ d'œuvres.
Articles déposés en accès libre sur l'archive ouverte des universités françaises (HAL) — gage d'activité de recherche en France.
Real-World Outcomes of First-Line Immune-Based Combination Therapies in Bone-Metastatic Clear Cell Renal Cell Carcinoma
2026ArticleClinical Genitourinary Cancer
A Comprehensive Assessment of Cancer Patient Performance Status Documentation in a Large, Multicentre Hospital System
2026ArticleJournal of Evaluation in Clinical Practice
Implementation and evaluation of a peer-to-peer support program in oncology: study protocol for the PaRole Onco France model
2026ArticleArchives of Public Health
Emergency cancer diagnosis in Paris: A cross‐sectional study using AP‐HP data
2025ArticleInternational Journal of Cancer
Adjuvant chemotherapy and hormonotherapy versus adjuvant hormonotherapy alone for women aged 70 years and older with high-risk breast cancer based on the genomic grade index (ASTER 70s): a randomised phase 3 trial
2025ArticleThe Lancet
Lenvatinib Plus Pembrolizumab and Chemotherapy Versus Chemotherapy in Advanced Metastatic Gastroesophageal Adenocarcinoma: The Phase III, Randomized LEAP-015 Study
2025ArticleJournal of Clinical Oncology
First-line chemotherapy with selective internal radiation therapy for intrahepatic cholangiocarcinoma
2025ArticleJHEP Reports Innovation in Hepatology
Bridging the digital divide for outpatients treated with anticancer chemotherapy: a retrospective quantitative and qualitative analysis of an adapted electronic Patient Reported Outcome program
2025ArticleSupportive Care in Cancer
Source : HAL — archive ouverte CCSD/CNRS (couvre articles, chapitres EMC, communications congrès, thèses).
GHU APHP HM SITE HENRI MONDOR
51 AV MAL DE LATTRE DE TASSIGNY, 94010 CRETEIL CEDEX
Secteur de conventionnement non disponible (médecin hospitalier ou non présent dans l'Annuaire santé CNAM des libéraux conventionnés).
Lien Doctolib = recherche Google site:doctolib.fr (le 1er résultat est presque toujours le profil correct s'il existe).
Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2023
PURPOSE In patients with resectable gastric/gastroesophageal junction (GEJ) adenocarcinoma, surgery plus perioperative platinum-based chemotherapy is the standard of care. Perioperative chemotherapy remains debatable for gastric/GEJ adenocarcinoma with deficient mismatch repair (dMMR)/microsatellite instability–high (MSI-H). PATIENTS AND METHODS NEONIPIGA (ClinicalTrials.gov identifier: NCT04006262 ) phase II study evaluated neoadjuvant nivolumab 240 mg once every two weeks ×6 and ipilimumab 1 mg/kg once every six weeks ×2, followed by surgery and adjuvant nivolumab 480 mg once every four weeks (nine injections) in patients with locally advanced resectable dMMR/MSI-H, clinical (c) tumor (T)2-T4 node (N)x metastasis (M)0 gastric/GEJ adenocarcinoma. The primary end point was a pathological complete response (pCR) rate. RESULTS Between October 2019 and June 2021, 32 patients with dMMR/MSI-H gastric/GEJ adenocarcinoma were enrolled. The median age was 65.5 years (range, 40-80). Clinical stages were cT2-T3N0 (n = 9), cT2-T3N1 (n = 22), and cT3N1M1 (n = 1, wrongly included). With a median follow-up of 14.9 months (95% CI, 10.6 to 17.6), 32 patients received neoadjuvant immunotherapy (27 patients completed all cycles). Neoadjuvant therapy-related grade 3/4 adverse events occurred in six patients (19%). Twenty-nine patients underwent surgery; three did not have surgery and had complete endoscopic response with tumor-free biopsies and a normal computed tomography scan (two refused surgery and one had metastasis at inclusion). The rate of surgical morbidity (Clavien-Dindo classification) was 55% (one postoperative death occurred). All 29 patients had an R0 resection, and 17 (58.6%; 90% CI, 41.8 to 74.1) had pCR (pathological T0N0). Becker tumor regression grades 1a, 1b, 2, and 3 were observed in 17 patients, three (including two pathological T0N1), two, and seven patients, respectively. Of the 29 patients with surgery, 23 received adjuvant nivolumab. At database lock, no patient had relapse and one died without relapse. CONCLUSION Nivolumab and ipilimumab-based neoadjuvant therapy is feasible and associated with no unexpected toxicity and a high pCR rate in patients with dMMR/MSI-H resectable gastric/GEJ adenocarcinoma.
European urology · 2023
Journal of the National Comprehensive Cancer Network : JNCCN · 2023
Background: The impact of adapted physical activity (APA) on health-related quality of life (HRQoL) in patients with advanced pancreatic ductal adenocarcinoma (aPDAC) is unknown. This study evaluated whether APA in addition to standard care improved HRQoL in patients who have aPDAC who are receiving first-line chemotherapy. Patients and Methods: Patients with locally advanced/metastatic PDAC and an ECOG performance status of 0 to 2 were randomized (1:1) to receive standard care (standard arm) or standard care plus a home-based 16-week APA program (APA arm). The primary objective was the effect of the APA program on 3 dimensions of the EORTC QLQ-C30: global health status, physical function, and fatigue at week 16 (W16), with a one-sided type I error of 0.017 for each dimension. The primary HRQoL analysis was performed in patients with available baseline and W16 scores for the dimensions (ie, the modified intention-to-treat population 1 [mITT1]), and secondary longitudinal HRQoL analyses using the mixed model for repeated measures (MMRM) and time until definitive deterioration (TUDD) methods were performed in the mITT1 population and in patients with baseline and at least one follow-up questionnaire (mITT2 population). A difference of ≥5 points was considered to be clinically relevant. Results: Of 326 included patients, 313 were randomized to the standard (n=157) or APA (n=156) arms. In the mITT1 population (n=172), the mean differences in global health status, physical function, and fatigue at W16 adjusted from baseline were −0.98 (SD, 23.9; P=.39), −2.08 (SD, 21.3; P=.26), and 4.16 (SD, 29.2; P=.17), respectively, showing a non–statistically significant benefit with APA. In the mITT2 population (n=259), APA was associated with statistically significant and clinically relevant improvement in 5 and 8 dimensions of the HRQoL in the longitudinal MMRM and TUDD analyses, respectively. Conclusions: APA improved several dimensions of HRQoL in patients with aPDAC receiving first-line chemotherapy and standard care.
Source PubMed · Recherche par auteur (homonymes possibles, vérifier l'affiliation).
Bulletin du cancer · 2026 · English Abstract
Adda F, Klausner G, Reghdi J, Tang E, et al.
Virchows Archiv : an international journal of pathology · 2025 · Journal Article
Favre L, Nguyen CT, Calderaro J, Pelletier R, et al.
Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2024 · Journal Article
Rohr O, Priou S, Chatellier G, Babai S, et al.
BMJ supportive & palliative care · 2024 · Letter
Cassam Chenai T, El Mejdani M, Cohen A, Priou S, et al.
International journal of cancer · 2023 · Multicenter Study
Kempf E, Priou S, Lamé G, Laurent A, et al.
Cancer medicine · 2023 · Multicenter Study
Guével E, Priou S, Lamé G, Wassermann J, et al.
Journal of geriatric oncology · 2023 · Multicenter Study
Aparicio T, Layese R, Hemery F, Tournigand C, et al.
European journal of cancer (Oxford, England : 1990) · 2022 · Journal Article
Priou S, Lamé G, Zalcman G, Wislez M, et al.
Molecular oncology · 2022 · Journal Article
Favre L, Cohen J, Calderaro J, Pécriaux A, et al.
Signal transduction and targeted therapy · 2026 · Journal Article
Chibaudel B, Dourthe LM, André T, Henriques J, et al.
British journal of cancer · 2026 · Journal Article
Blanchet B, Puszkiel A, Jouinot A, Bennamoun M, et al.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2025 · Journal Article
Hammel P, Metges JP, Macarulla Mercade T, Garcia-Carbonero R, et al.
Journal of evaluation in clinical practice · 2026 · Journal Article
Lamé G, Mejdani ME, Cohen A, Priou S, et al.
Archives of public health = Archives belges de sante publique · 2026 · Journal Article
Busnel Y, Pomey MP, Termoz A, Christophe V, et al.
JHEP reports : innovation in hepatology · 2025 · Journal Article
Adamus N, Edeline J, Henriques J, Fares N, et al.
Liver international : official journal of the International Association for the Study of the Liver · 2024 · Journal Article
Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2025 · Journal Article
Boiteau C, Alarcon N, Joly C, Fenioux C, et al.
European urology · 2023 · Clinical Trial, Phase III
Grivas P, Kopyltsov E, Su PJ, Parnis FX, et al.
Cancer research communications · 2025 · Journal Article
Vienot A, Vernerey D, Bouard A, Klajer E, et al.
Biometrical journal. Biometrische Zeitschrift · 2023 · Journal Article
Rustand D, van Niekerk J, Rue H, Tournigand C, et al.
Therapeutic advances in medical oncology · 2025 · Journal Article
Valery M, Edeline J, Henriques J, Antoun L, et al.
Journal of geriatric oncology · 2023 · Multicenter Study
Aparicio T, Layese R, Hemery F, Tournigand C, et al.
BMC cancer · 2024 · Meta-Analysis
Marty S, Lamé G, Guével E, Priou S, et al.
Health and quality of life outcomes · 2023 · Systematic Review
Depotte L, Caroux M, Gligorov J, Canouï-Poitrine F, et al.
Clinical genitourinary cancer · 2026 · Journal Article
Harba A, Moinard-Butot F, Auclin E, Barthélémy P, et al.
International journal of cancer · 2023 · Multicenter Study
Kempf E, Priou S, Lamé G, Laurent A, et al.
Journal of the National Comprehensive Cancer Network : JNCCN · 2023 · Journal Article
Neuzillet C, Bouché O, Tournigand C, Chibaudel B, et al.
BMC cancer · 2024 · Meta-Analysis
Marty S, Lamé G, Guével E, Priou S, et al.
Dataset for: Multivariate joint frailty model for the analysis of nonlinear tumor kinetics and dynamic predictions of death
The RECIST criteria are used as standard guidelines for the clinical evaluation of cancer treatments. The assessment is based on the anatomical tumor burden: change in size of target lesions and evolution of non-target l
Adverse event load, onset, and maximum grade: A novel method of reporting adverse events in cancer clinical trials
BackgroundCurrent adverse event reporting practices do not document longitudinal characteristics of adverse effects, and alternative methods are not easily interpretable and have not been employed by clinical trials. Int
Adverse event load, onset, and maximum grade: A novel method of reporting adverse events in cancer clinical trials
BackgroundCurrent adverse event reporting practices do not document longitudinal characteristics of adverse effects, and alternative methods are not easily interpretable and have not been employed by clinical trials. Int
Association between overweight, obesity, and quality of life of patients receiving an anticancer treatment for prostate cancer: a systematic literature review
Abstract Background Prostate cancer (PCa) and obesity are two ever-increasing public health issues that can independently impair the quality of life (QOL) of affected patients. Our objective was to evaluate the impact of
Multidisciplinary management of patients with cancer in France: The SINPATIC qualitative study
Health policymakers have tried to improve the care pathway for cancer patients by improving collaboration between participating healthcare professionals by involving the general practitioner (GP). To explore how patients
Association between overweight, obesity, and quality of life of patients receiving an anticancer treatment for prostate cancer: a systematic literature review
Abstract Background Prostate cancer (PCa) and obesity are two ever-increasing public health issues that can independently impair the quality of life (QOL) of affected patients. Our objective was to evaluate the impact of
Source : DataCite — DOIs pour datasets, logiciels, protocoles, registres patient. Hors articles (déjà couverts).
Journal for immunotherapy of cancer · 2025 · Journal Article
Depotte L, Nay P, Borg C, Meurisse A, et al.
Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver · 2025 · Clinical Trial Protocol
Lecomte T, Giraudeau B, Phelip JM, Tournigand C, et al.
Journal of the National Comprehensive Cancer Network : JNCCN · 2023 · Journal Article
Neuzillet C, Bouché O, Tournigand C, Chibaudel B, et al.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2023 · Clinical Trial
Tournigand C, André T, Achille E, Lledo G, et al.
Biometrical journal. Biometrische Zeitschrift · 2023 · Journal Article
Rustand D, van Niekerk J, Rue H, Tournigand C, et al.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2023 · Clinical Trial, Phase II
André T, Tougeron D, Piessen G, de la Fouchardière C, et al.
Lebeaud A, Antoun L, Paccard JR, Edeline J, et al.
Clinical pharmacokinetics · 2024 · Journal Article
Alexandre J, Oudard S, Golmard L, Campedel L, et al.
The oncologist · 2023 · Journal Article
Frelaut M, Paillaud E, Beinse G, Scain AL, et al.
Journal of gastrointestinal oncology · 2023 · Journal Article
Piquemal D, Bruno R, Bournet B, Ghiringhelli F, et al.
Clinics and research in hepatology and gastroenterology · 2023 · Journal Article
Jenvrin A, Galletto-Pregliasco A, Audureau E, Pujals A, et al.
Health and quality of life outcomes · 2023 · Systematic Review
Depotte L, Caroux M, Gligorov J, Canouï-Poitrine F, et al.